MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine

MOUNTAIN VIEW, Calif., Jan. 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ), an emerging pharmaceutical company, today announced that it has completed the special protocol assessment (SPA) process with the U.S. Food and Drug Administration (FDA) for the first Phase 3 cl...

MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference

...clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and map0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its prop...

MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference

...clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and map0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its prop...

MAP Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference

...clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and map0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its prop...

MAP Pharmaceuticals Reports 2008 Fourth Quarter and Year End Financial Results

...y results from our first Phase 3 clinical trial of map0004 for the potential treatment of migraine," said Tim...ventional nebulized budesonide. map0004 Received a Special Protocol Asses...cy portion of its first Phase 3 clinical trial for map0004 during the first half of 2009. At that time the c...

MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca

...se 3 clinical trials. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and map0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its prop...

MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference

...y has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and map0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug...

MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results

... -- MAP0004: Initiated enrollment in a Phase 3 clinical trial to evaluate map0004 for the potential treatment of migraine, pursuant to a Special Protocol Ass...tics of MAP0004 in adult asthmatics, and presented three posters related to map0004 at the European Headache and Migraine Trust International Congress. Third...

MAP Pharmaceuticals Reports Second Quarter of 2008 Financial Results

... Initiated a Phase 3 clinical program to evaluate map0004 for the potential treatment of migraine, ... safety, tolerability and pharmacokinetics of map0004 in adult asthmatics in Current Medical Re...uating the safety and pharmacokinetics of map0004 in adults in Headache. -- Delivered over 15 ...

MAP Pharmaceuticals Reports First Quarter of 2008 Financial Results

...ng UDB to the currently marketed conventional nebulized budesonide. For our map0004 migraine program, we received a special protocol assessment (SPA) from the ... release contains forward-looking statements, including with respect to our map0004 migraine program. Actual results may differ materially from current expecta...

MAP0004 in Medical Technology

MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion

MOUNTAIN VIEW, Calif., July 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) announced that the positive results from a Phase 2 study evaluating the safety, tolerability and pharmacokinetics of MAP0004 in adult asthmatics were published in the July issue of Current Medic...

MAP Pharmaceuticals to Present MAP0004 Phase 2 Clinical Data at the American Headache Society Meeting

MOUNTAIN VIEW, Calif., June 05, 2007 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its MAP0004 migraine therapy clinical program at the 49th Annual American Headache Society Meeting at the Hyatt Regency Chicago in Chicago, Illinois. The poster pre...

MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints

...clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and map0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its prop...

AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints

...clinical development. Unit Dose Budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and map0004 is being developed for the potential treatment of migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its prop...

MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine

...initiated its Phase 3 clinical program to evaluate map0004 as a potential treatment for migraine. map0004 is orally inhaled and self-administered at home us...er. In the company's prior Phase 2 efficacy study, map0004 provided pain relief in as fast as 10 minutes, wit...

MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting

...udy results were among six posters relating to the map0004 program that the Company presented at the American...Boston, MA. In this receptor pharmacology study, map0004 stimulated receptors that relieve migraine at leve... effects frequently seen with IV DHE. In addition, map0004 did not affect receptors that have a role in regul...

MAP0004 in Biological Technology

MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine

MOUNTAIN VIEW, Calif., Jan. 26 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that it has completed patient enrollment in the efficacy portion of its initial Phase 3 clinical trial evaluating MAP0004, the company's novel, orally inhaled product candidate ...

MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs

...Dose Budesonide (UDB) for children with asthma and map0004 for the acute treatment of migraine. For UDB, all...th no significant adverse events reported. map0004 Phase 3 Program MAP Pharmaceuticals expects...approximately 850 migraine sufferers is evaluating map0004 as a potential acute treatment for migraine. Pati...